109 related articles for article (PubMed ID: 27878207)
1. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
Berntorp E
Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.
Calvez T; Laurian Y; Goudemand J
J Thromb Haemost; 2008 Feb; 6(2):390-2. PubMed ID: 18036187
[No Abstract] [Full Text] [Related]
3. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?
Di Minno G; Coppola A
Blood Transfus; 2011 May; 9 Suppl 2(Suppl 2):s14-20. PubMed ID: 21839028
[No Abstract] [Full Text] [Related]
4. The World Health Organisation's list of essential medicines and haemophilia treatment products.
Farrugia A
Haemophilia; 2023 Nov; 29(6):1387-1389. PubMed ID: 37807613
[No Abstract] [Full Text] [Related]
5. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Meeks SL; Batsuli G
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
[TBL] [Abstract][Full Text] [Related]
7. Do the SIPPET study results apply to the patients I treat?
Fischer K; Blatny J
Haemophilia; 2017 May; 23(3):348-349. PubMed ID: 27928863
[No Abstract] [Full Text] [Related]
8. A new era of treatment for patients with haemophilia A?
Klamroth R
Hamostaseologie; 2017 Aug; 37(3):216-218. PubMed ID: 27885373
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
Iannazzo S; Cortesi PA; Crea R; Steinitz K; Mantovani LG; Gringeri A
Blood Coagul Fibrinolysis; 2017 Sep; 28(6):425-430. PubMed ID: 27898515
[TBL] [Abstract][Full Text] [Related]
10. Summary report of the First International Conference on inhibitors in haemophilia A.
Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
[No Abstract] [Full Text] [Related]
11. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
[TBL] [Abstract][Full Text] [Related]
12. What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
Janbain M; Pipe S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):648-649. PubMed ID: 27913541
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
[TBL] [Abstract][Full Text] [Related]
15. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.
Iorio A; Fischer K; Makris M
Br J Haematol; 2017 Jul; 178(1):20-31. PubMed ID: 28387451
[TBL] [Abstract][Full Text] [Related]
16. SIPPET: methodology, analysis and generalizability.
Peyvandi F; Mannucci PM; Palla R; Rosendaal FR
Haemophilia; 2017 May; 23(3):353-361. PubMed ID: 28306186
[TBL] [Abstract][Full Text] [Related]
17. New findings on inhibitor development: from registries to clinical studies.
Peyvandi F; Ettingshausen CE; Goudemand J; Jiménez-Yuste V; Santagostino E; Makris M
Haemophilia; 2017 Jan; 23 Suppl 1():4-13. PubMed ID: 27990784
[TBL] [Abstract][Full Text] [Related]
18. Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.
Ragni MV; Yabes JG; Fogarty PF; Josephson NC; Kessler CM; Neff AT; Raffini L; Brummel-Ziedins K; Moore CG
Haemophilia; 2017 Jan; 23(1):e43-e46. PubMed ID: 27943502
[No Abstract] [Full Text] [Related]
19. Pathophysiology of hemophilic arthropathy and potential targets for therapy.
Pulles AE; Mastbergen SC; Schutgens RE; Lafeber FP; van Vulpen LF
Pharmacol Res; 2017 Jan; 115():192-199. PubMed ID: 27890816
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance induction: What have we learned over time?
Brackmann HH; White GC; Berntorp E; Andersen T; Escuriola-Ettingshausen C
Haemophilia; 2018 Apr; 24 Suppl 3():3-14. PubMed ID: 29543371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
